Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FGFR1 positive |
Therapy | Fexagratinib + Vistusertib |
Indication/Tumor Type | head and neck squamous cell carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR1 positive | head and neck squamous cell carcinoma | sensitive | Fexagratinib + Vistusertib | Preclinical - Cell culture | Actionable | In a preclinical study, AZD4547 and Vistusertib (AZD2014) synergistically inhibited survival of FGFR1-dependent head and neck squamous cell carcinoma cells in culture (PMID: 26359452). | 26359452 |
PubMed Id | Reference Title | Details |
---|---|---|
(26359452) | Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC. | Full reference... |